CJC 1295

CJC 1295 is a synthetic peptide derived from growth hormone-releasing hormone (GHRH). It consists of 30 amino acids and was designed to increase the stability and duration of GHRH activity by binding to albumin and extending its half-life.

CJC 1295 is purported to promote muscle growth, reduce body fat, and improve recovery by increasing growth hormone and insulin-like growth factor 1 (IGF-1) levels. It is also believed to support better sleep and overall physical performance.

Clinical studies indicate that CJC‑1295 significantly raises levels of Growth Hormone (GH) and Insulin‑like Growth Factor‑1 (IGF-1) in healthy adults. One study reported 2- to 10-fold increases in GH for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days following a single dose ¹. Another trial showed that trough (basal) GH levels increased roughly 7.5-fold, mean GH levels rose 46 %, and IGF-1 rose about 45 % one week post-injection, while preserving normal GH pulsatility ².

These hormonal changes are often interpreted as beneficial for muscle growth and fat loss. Because GH and IGF-1 are involved in protein synthesis and metabolic regulation, higher levels may support lean muscle mass and reduced body fat. The sustained elevation of GH/IGF-1 after CJC-1295 suggests it may assist in improving body composition and physical recovery. Overall, CJC‑1295 shows potential for enhancing anabolic and metabolic effects in adults through prolonged GH and IGF-1 elevation.

In human clinical studies, CJC 1295 was generally well tolerated, and most reported side effects were mild and temporary. The most common reactions included injection-site redness, pain, and swelling, which typically resolved without treatment ³. Some participants also experienced transient headaches and mild flu-like symptoms.

However, no serious or long-term adverse effects were reported in these studies, and laboratory findings did not show evidence of toxicity or organ dysfunction. Follow-up data indicated that hormone levels returned to baseline without persistent abnormalities after treatment cessation.